Teknova's 8-K Confirms $40M Offering, 15% Share-Count Increase and Preliminary Q3 Beat
TKNO has more than doubled off its 52-week low of $1.91 on elevated volume (17× avg).
Summary
Teknova's 8-K formalizes the $40M offering of 8M shares at $5.00 — about 15% dilution — alongside preliminary Q3 revenue of $12.5M-$12.7M, up 19-21% year over year, and $16.6M of cash at quarter-end.
Key Events · Financing and Capital Events · TKNO
-
$40M Offering Terms Finalized
8,000,000 shares sold at $5.00 for $40.0M gross, with a 30-day underwriter option on 1,200,000 more shares taking the maximum to $46.0M. Closing expected on or about October 22, 2026.
-
Roughly 15% Share-Count Increase
Post-deal shares outstanding of 61,702,534 versus 53,702,534 at September 30, 2026 — 8.0M new shares, about 15% dilution. Net proceeds of roughly $37.6M after a 6.0% underwriting discount ($4.70 per share to underwriters) and about $380,000 of expenses.
-
Preliminary Q3 Revenue Up 19-21%
Revenue estimated at $12.5M-$12.7M with gross margin of 36.0%-38.0%, a 500-700 bp improvement year over year. Adjusted EBITDA loss of $1.0M-$1.2M and net loss of $3.494M-$3.694M.
-
Cash Position and Use of Proceeds
$16.6M of cash and short-term investments as of September 30, 2026. Proceeds earmarked for general corporate purposes, potentially including repayment of outstanding debt; 2026 revenue guidance of $45M-$47M and an Adjusted EBITDA-positive quarter targeted before the end of 2027.
Analysis · TKNO · Life Sciences
The $40M raise was already public, but this 8-K locks in the terms: 8M shares at $5.00, a 6.0% underwriting discount ($4.70 net per share), and a 30-day option on 1.2M more shares that would take gross proceeds to $46M. Post-deal shares outstanding rise to 61.7M from 53.7M at September 30 — roughly 15% dilution — against a company that had only $16.6M of cash and short-term investments at quarter-end. Offsetting that is the preliminary Q3 print: revenue of $12.5M-$12.7M is up 19-21% year over year, gross margin of 36-38% marks a 500-700 bp improvement, and the Adjusted EBITDA loss narrows to $1.0M-$1.2M. The raise buys runway toward the company's stated goal of an Adjusted EBITDA-positive quarter before the end of 2027, though existing holders pay for it in dilution. Directors and officers are locked up until January 19, 2027, so there is no insider-selling overhang near term.
How filings like this one have moved
In the 30 days to Oct 21, 2026, 28.9% of the 1511 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.54%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, TKNO was trading at $5.65 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $314.1M. The 52-week trading range was $1.91 to $9.48. This filing was assessed with negative market sentiment and an importance score of 7 out of 10.